Influenza Vaccine Feasibility Study in Children With Persistent Asthma
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This study is designed to note whether a larger safety study using quadrivalent live
attenuated influenza vaccine (LAIV4) versus quadrivalent inactivated influenza vaccine
(IIV4)(FLUARIX®), would be feasible in children with persistent asthma. Half of the patients
in this study will receive the FLUARIX® influenza vaccine, while the other half will receive
a cell cultured quadrivalent inactivated influenza vaccine (ccIIV4)(Flucelvax®) being used as
a surrogate for LAIV4.
Phase:
Phase 4
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center
Collaborators:
Centers for Disease Control and Prevention Children's Hospital Medical Center, Cincinnati Duke University